TRCT
IMDZ

Tower Research Capital (TRC)’s Immune Design Corp. IMDZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,204
Closed -$2K – 4764
2018
Q4 		$2K Sell
1,204
-11,344
-90% -$19.7K ﹤0.01% 3527
2018
Q3 		$43K Buy
+12,548
New +$47.1K ﹤0.01% 1862
2018
Q1 		– Sell
-5,333
Closed -$21K – 4329
2017
Q4 		$21K Buy
5,333
+3,108
+140% +$16.9K ﹤0.01% 2053
2017
Q3 		$23K Buy
+2,225
New +$21.9K ﹤0.01% 2667
2017
Q2 		– Sell
-22
Closed – – 4039
2017
Q1 		$0 Sell
22
-1,997
-99% -$11.5K ﹤0.01% 4640
2016
Q4 		$11K Sell
2,019
-9,115
-82% -$64.4K ﹤0.01% 2622
2016
Q3 		$85K Buy
11,134
+10,531
+1,746% +$77K 0.01% 883
2016
Q2 		$5K Buy
603
+128
+27% +$1.6K ﹤0.01% 3477
2016
Q1 		$6K Sell
475
-320
-40% -$3.69K ﹤0.01% 2635
2015
Q4 		$16K Buy
+795
New +$13.7K ﹤0.01% 1588
2015
Q3 		– Sell
-1,012
Closed -$21K – 5648
2015
Q2 		$21K Buy
1,012
+215
+27% +$5.08K ﹤0.01% 2077
2015
Q1 		$17K Buy
+797
New +$20.8K ﹤0.01% 2410

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Tower Research Capital (TRC)'s IMDZ Position: Q1 2019 in Review

Tower Research Capital (TRC) sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 1,204 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in IMDZ in Q1 2015 and held it in 12 quarters. The position peaked at $85K in Q3 2016. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

  • Tower Research Capital (TRC) reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,204 Immune Design Corp. shares in Q1 2019, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in Immune Design Corp. in Q1 2015 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Immune Design Corp. position peaked at $85K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2019, filed 14 May 2019.